NPY treatments inhibited cell proliferation of CCA lines, Mz-ChA-1, SG231, HuH-28, CCLP, HuCCT1, and TFK-1 cells, via elevation of IP3 secretion and PKC-α activation [87]. Here, PRKCA is linked to cholangiocarcinoma.